Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicityClinical trials underway in solid tumor cancers,...
-
NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
-
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
-
No evidence of neurotoxicity or cytokine release syndromeEarly signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myelomaiNKTs...
-
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
-
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...
-
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic,...
-
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...